EN DE
Watch Personalis Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Personalis Inc (PSNL) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of Personalis Inc stock $9.80, price $14.80, that is 33.8% below the price, quality 34 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

PI Personalis Inc logo Thin data Nov 17, 2026

Personalis Inc

PSNL · US

Expensive (fair value 34% below the price) and weak company, but rising price: meets 1 of 3 rules.

Get notified free when this changes
Rising price (uptrend) 
Low debt 
Revenue last quarter +77% vs. a year ago. 
Insiders sold $7.8M (6M) 
Fair value $9.80 · Overvalued 
Quality 34/100 
Weak Growth (revenue 5y −2.4 %/yr in USD) 
Loss-making · -147.7% net margin (TTM) 
Negative free cash flow 
Trails peers (2/10) 
Narrow moat 9/100
Recent news very negative 
Thin data 
Estimate
Watch Personalis Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$22.43 $0.9300 Fair Value $9.80 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 17, 2026.

How to read this chart

60‑month range $0.9300 – $22.43 · fair‑value band $7.35 – $12.25 · the $14.80 price screens above the $9.80 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 17, 2026.

Follow Personalis in your weekly email

Every Wednesday you see whether Personalis is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally.

Show moreShow less

The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample.

It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for the detection of MRD; and NeXT Dx, a tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient.

In addition, the company performs whole exome sequencing of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing on human samples for research projects, such as population sequencing initiatives.

Its services are used by pharmaceutical companies for translational research, biomarker discovery, the development of personalized cancer therapies, and for clinical trials, as well as tests are used by physicians to detect residual or recurrent cancer in patients, monitor cancer response to therapy, and uncover insights for therapy selection.

The company's customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and cancer patients. The company has strategic collaboration with Tempus AI, Inc. to bring testing to colorectal cancer patients.

Personalis, Inc. was incorporated in 2011 and is headquartered in Fremont, California.

Stock analysis

Personalis Inc (PSNL) currently trades at $14.80, while our estimate is $9.80, 34% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $7.35 (bear) to $12.25 (bull), the price of $14.80 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 34/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Personalis Inc reported revenue of $69.6M in FY2025 versus $85.5M in FY2021, a compound −5.0%/yr. Reported net income was −$81.3M in FY2025.

Key figures

Market cap $1.6B Small · P/S ratio 21.4 · EPS (TTM) $−1.16 · Net margin −148% · Return on equity −62.1% · Return on assets (EBIT) −31.3% (5-year average) · Operating margin −139% · Revenue (TTM) $80.8M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 9 out of 100 (medium confidence).

What moves the price

The share trades about 19% below its 52-week high and 194% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −9% fair-value upside, at −34%, PSNL screens richer than that median.

Fair Value

Bear $7.35 Fair Value $9.80 Bull $12.25
Price $14.80 · Downside -33.8%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 34/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 1
How much profit the company makes from its sales and capital
Quality Growth 20
Are margins and returns getting better?
Cashflow 9
Do the profits arrive as real cash?
Financial strength 100
Debt, balance sheet and risk of trouble
Investment 74
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Price momentum 86
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 87
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, 4 officers or directors sold shares worth $7.8M and none bought.

  • SaleChristopher M HallChief Executive Officer, Director5× since May 28, 2026: 336,571 shares, avg. $13.39$4.5MNov 3, 2026
  • SaleAaron TachibanaCFO AND COO7× since Nov 25, 2025: 242,832 shares, avg. $11.75$2.9MSep 18, 2026
  • SaleRichard ChenPresident and CMO2× since Jul 15, 2026: 103,998 shares, avg. $15.19$1.6MSep 18, 2026
  • SaleStephen Michael MooreSVP and Chief Legal Officer2,068 shares at $16.22$33,543Sep 18, 2026
  • BuyTempus AI, Inc.10% owner320,267 shares at $8.55$2.7MDec 22, 2025

Plus 8 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 16, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−17.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.4%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+28.5%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−53.6% (2020) → −126.4% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

PSNL screens overvalued: fair value 34% below the price. Compare with Thermo Fisher Scientific Inc →

Earlier news

News mood ⓘNews mood, the average tone of recent news (98 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Very negative
Recent news coverage is unusually downbeat.

Compare Personalis Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 151 stocks

Beats the industry median on 2/9 measures
Overall it trails its industry peers.
Valuation
Quality Score 34 · Bottom 25%
Fair Value upside −33.8% · Below median
Profitability
Return on assets −24.3% · Bottom 25%
Net margin (12 months) −147.7% · Bottom 25%
Operating margin (12 months) −138.8% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 76.6% · Top 25%
Balance sheet
Debt / equity 0.00× · Lowest 25%

Valuation Multiplesvs Diagnostics & Research median · lower = cheaper

P/B 6.14× · Priciest 25%
P/S (12 months) 19.85× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 19
FUTURE (revenue growth)100 · sector 40
PAST (return on equity)0 · sector 9
HEALTH (low debt)100 · sector 95
DIVIDEND (yield)0 · sector 33

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Illumina, Inc ILMN $198.00 $227.71 +15% vs PSNL
WuXi AppTec Co 603259 ¥144.41 ¥164.66 +14% vs PSNL
IQVIA Holdings IQV $264.73 $291.63 +10% vs PSNL
Thermo Fisher Scientific Inc TMO $691.33 $686.04 −1% vs PSNL
Danaher Corporation DHR $229.91 $209.18 −9% vs PSNL
IDEXX Laboratories, Inc IDXX $700.65 $496.48 −29% vs PSNL
Lonza Group LONN CHF 670.20 CHF 259.80 −61% vs PSNL
Mettler-Toledo International Inc MTD $1,727 $655.06 −62% vs PSNL
Agilent Technologies, Inc A $172.92 $64.20 −63% vs PSNL
Waters Corporation WAT $453.42 $91.26 −80% vs PSNL

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Personalis Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Personalis Inc Fair Value". https://www.fairvalue-calculator.com/stock/PSNL

Frequently asked questions

Is Personalis Inc (PSNL) overvalued or undervalued?
As of Nov 17, 2026, our estimate of fair value is $9.80 versus a price of $14.80, about 34% lower (overvalued).
What is the fair value of PSNL?
Our estimate for Personalis Inc is $9.80 (as of Nov 17, 2026), built from audited fundamentals. The current price: $14.80.
What is the quality score of PSNL?
Personalis Inc has a Quality Score of 34/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Personalis Inc (PSNL)?
Our calculated price target is the estimate of $9.80 (as of Nov 17, 2026). Cautious scenario $7.35, optimistic scenario $12.25. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Personalis Inc stock forecast for 2026?
Our estimate puts fair value at $9.80, about 34% lower versus a price of $14.80 (overvalued). Cautious scenario $7.35, optimistic scenario $12.25. The calculation is refreshed regularly with new filings.
What is the revenue of Personalis Inc (PSNL)?
Personalis Inc reported trailing-twelve-month revenue of about $80.8M (latest available figure, as of Nov 17, 2026).
What is the intrinsic value of Personalis Inc (PSNL)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Personalis Inc it is $9.80 per share (as of Nov 17, 2026), against a price of $14.80.
Is Personalis Inc stock overvalued or undervalued in 2026?
As of Nov 17, 2026, PSNL trades above its calculated fair value: price $14.80, fair value $9.80, a gap of about −34% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PSNL?
No. The price is what the market pays today ($14.80); the fair value is what the company's own numbers justify ($9.80). For Personalis Inc the two are $5.00 per share apart. That gap is exactly why we show both numbers side by side.
How much is Personalis Inc worth?
The market values Personalis Inc at about $1.6B (market capitalisation, as of Nov 17, 2026). Per share that is $14.80; our models calculate a fair value of $9.80 per share.
What do the bullish and bearish scenarios say about PSNL?
Our models span a range for Personalis Inc: cautious scenario $7.35, base $9.80, optimistic $12.25 per share (as of Nov 17, 2026, price $14.80). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Personalis Inc (PSNL)?
Balance-sheet figures for Personalis Inc (as of Nov 17, 2026): return on equity −62.1%, debt of 0.00 per unit of equity. They feed the Quality Score of 34/100, which measures business quality independently of the share price.
How far is PSNL from its 52-week high?
Personalis Inc trades at $14.80, about 19% below its 52-week high of $18.38 and 194% above the low of $5.04 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of $9.80 is for.
Which stocks are comparable to Personalis Inc?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Lonza Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Personalis Inc stock attractive at the current price?
The data as of Nov 17, 2026: price $14.80, calculated fair value $9.80 (−34%), Quality Score 34/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. Personalis Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Personalis Inc (PSNL)?
The closing price on Nov 16, 2026 was $14.80. Our estimate is $9.80, about 34% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Personalis Inc right now?
The price sits above even our optimistic bull case ($12.25). The favourable scenario is already priced in. Weak quality (34/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Personalis Inc

How large is the market capitalisation of Personalis Inc (PSNL)?
The market capitalisation of Personalis Inc is $1.6B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Personalis Inc (PSNL)?
The price-to-sales ratio of Personalis Inc is 21.4 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Personalis Inc (PSNL)?
Earnings per share at Personalis Inc are $−1.16. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Personalis Inc (PSNL)?
The net margin of Personalis Inc is −148% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Personalis Inc (PSNL)?
The return on equity (ROE) of Personalis Inc is −62.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Personalis Inc (PSNL)?
On an EBIT basis the return on assets of Personalis Inc is −31.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Personalis Inc (PSNL)?
The operating margin of Personalis Inc is −139% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Personalis Inc (PSNL)?
Revenue at Personalis Inc is growing 76.6% versus a year earlier (3y avg +2.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Personalis Inc (PSNL) generate?
The free cash flow of Personalis Inc is −$79.5M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Personalis Inc (PSNL) hold?
Personalis Inc holds more cash than debt, $84.3M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Personalis Inc in the live analysis

One click puts Personalis Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.